Brittany M Lee

Dr. Brittany M Lee

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
BLBrittany M Lee
Brittany M Lee
CSCorinne Summers
Corinne Summers
KCKaren M. Chisholm
Karen M. Chisholm
SBSandra D. Bohling
Sandra D. Bohling
KLKasey J. Leger
Kasey J. Leger
ALAdam J. Lamble
Adam J. Lamble

27 March 2020 in Pediatrics
Verified
Journal Article
Closed access
PDF file
BLBrittany M Lee
Brittany M Lee
ATAmy Trowbridge
Amy Trowbridge
MMMacallagh McEvoy
Macallagh McEvoy
AWAaron Wightman
Aaron Wightman
SKStephanie A. Kraft
Stephanie A. Kraft
JCJonna D. Clark
Jonna D. Clark
The American Academy of Neurology believes that doctors have the right to do tests to evaluate whether a patient is brain dead even if the family does not consent. They argue that physicians have “both the moral authority and professional responsibility” to do such evaluations, just as they have the authority and responsibility to declare someone dead by circulatory criteria. Not everyone agrees. Truog and Tasker argue that apnea testing to confirm brain death has risks and that, for some families, those risks may outweigh the benefits. So, what should doctors do when caring for a patient whom they believe to be brain dead but whose parents refuse to allow testing to confirm that the patient meets neurologic criteria for death? In this article, we analyze the issues that arise when parents refuse such testing.

20 March 2024 in Pediatrics
Verified
Journal Article
Closed access
PDF file
BLBrittany M Lee
Brittany M Lee
ARAbby R. Rosenberg
Abby R. Rosenberg
JMJonathan M. Marron
Jonathan M. Marron
Advances in genomic testing have been pivotal in moving childhood cancer care forward, with genomic testing now a standard diagnostic tool for many children, adolescents, and young adults with cancer. Beyond oncology, the role of genomic testing in pediatric research and clinical care is growing, including for children with developmental differences, cardiac abnormalities, and epilepsy. Despite more standard use in their patients, pediatricians have limited guidance on how to communicate this complex information or how to engage parents in decisions related to precision medicine. Drawing from empirical work in pediatric informed consent and existing models of shared decision-making, we use pediatric precision cancer medicine as a case study to propose a conceptual framework to approach communication and decision-making about genomic testing in pediatrics. The framework relies on identifying the type of genomic testing, its intended role, and its anticipated implications to inform the scope of information delivered and the parents’ role in decision-making (leading to shared decision-making along a continuum from clinician-guided to parent-guided). This type of framework rests on practices known to be standard in other complex decision-making but also integrates unique features of genomic testing and precision medicine. With the increasing prominence of genomics and precision medicine in pediatrics, with our communication and decision-making framework, we aim to guide clinicians to better support their pediatric patients and their parents in making informed, goal-concordant decisions throughout their care trajectory.

Verified
Journal Article
Open access
PDF file
Jacqueline HunterJacqueline Hunter
Jacqueline Hunter
EREden Grace Robertson
Eden Grace Robertson
KHKate Hetherington
Kate Hetherington
DZDavid Ziegler
David Ziegler
GMGlenn M Marshall
Glenn M Marshall
CWClaire E Wakefield
Claire E Wakefield
Current literature/guidelines regarding the most appropriate term to communicate a cancer-related disease-causing germline variant in childhood cancer lack consensus. Guidelines also rarely address preferences of patients/families. We aimed to assess preferences of parents of children with cancer, genetics professionals, and pediatric oncologists towards terminology to describe a disease-causing germline variant in childhood cancer. Using semi-structured interviews we asked participants their most/least preferred terms from; ‘faulty gene,’ ‘altered gene,’ ‘gene change,’ and ‘genetic variant,’ analyzing responses with directed content analysis. Twenty-five parents, 6 genetics professionals, and 29 oncologists participated. An equal number of parents most preferred ‘gene change,’ ‘altered gene,’ or ‘genetic variant’ (n = 8/25). Parents least preferred ‘faulty gene’ (n = 18/25). Half the genetics professionals most preferred ‘faulty gene’ (n = 3/6); however this was least preferred by the remaining genetics professionals (n = 3/6). Many oncologists most preferred ‘genetic variant’ (n = 11/29) and least preferred ‘faulty gene’ (n = 19/29). Participants across all groups perceived ‘faulty gene’ as having negative connotations, potentially placing blame/guilt on parents/children. Health professionals described challenges selecting a term that was scientifically accurate, easily understood and not distressing to families. Lack of consensus highlights the need to be guided by families’ preferred terminology, while providing accurate explanations regarding implications of genetic findings.

6 August 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
BLBrittany M Lee
Brittany M Lee
NJNancy S. Jecker
Nancy S. Jecker
JMJonathan Marron
Jonathan Marron
ARAbby R. Rosenberg
Abby R. Rosenberg

3 April 2021 in The American Journal of Bioethics
Verified
Journal Article
Closed access
BLBrittany M Lee
Brittany M Lee
SKStephanie A. Kraft
Stephanie A. Kraft
Ethical issues in biomedical research are traditionally examined as distinct from those of clinical care. However, this traditional framing may obscure questions of equity and fairness in both rese...